BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eliglustat tartrate: Additional Phase II data

Three-year data from an open-label, international Phase II trial in 19 evaluable patients showed that oral eliglustat decreased spleen and liver volumes from baseline by 61% and 29%, respectively, increased mean hemoglobin levels by 2.6 g/dL and increased platelet counts by 91%. Data were presented at the Lysosomal Disease Network World Symposium in Las...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >